留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

新药时代自体造血干细胞移植在多发性骨髓瘤一线治疗中的地位

金媛媛 庄俊玲

金媛媛, 庄俊玲. 新药时代自体造血干细胞移植在多发性骨髓瘤一线治疗中的地位[J]. 协和医学杂志, 2018, 9(3): 219-223. doi: 10.3969/j.issn.1674-9081.2018.03.006
引用本文: 金媛媛, 庄俊玲. 新药时代自体造血干细胞移植在多发性骨髓瘤一线治疗中的地位[J]. 协和医学杂志, 2018, 9(3): 219-223. doi: 10.3969/j.issn.1674-9081.2018.03.006
Yuan-yuan JIN, Jun-ling ZHUANG. Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Medicines[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 219-223. doi: 10.3969/j.issn.1674-9081.2018.03.006
Citation: Yuan-yuan JIN, Jun-ling ZHUANG. Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Medicines[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 219-223. doi: 10.3969/j.issn.1674-9081.2018.03.006

新药时代自体造血干细胞移植在多发性骨髓瘤一线治疗中的地位

doi: 10.3969/j.issn.1674-9081.2018.03.006
基金项目: 

中国医学科学院创新工程项目 CAMS-2016-I2M-3-025

详细信息
    通讯作者:

    庄俊玲 电话:010-69155027, E-mail:zhuangjunling@pumch.cn

  • 中图分类号: R457.7;R733.3

Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Medicines

More Information
  • 摘要: 多发性骨髓瘤(multiple myeloma, MM)患者的总生存期(overall survival, OS)在过去20年间从3年延长至8~10年, 这得益于蛋白酶体抑制剂和免疫调节药物等的广泛应用。即使在新药时代, 自体造血干细胞移植(autologous stem cell transplantation, ASCT)仍可显著提高移植后反应率, 增加微小残留病变阴性率, 延长无进展生存期。ASCT对OS的影响在不同研究中结果并不一致, 这主要与进展后采用不同治疗方案有关。随着更多新药的出现, ASCT后复发患者会有更多选择。故新药时代, ASCT仍是MM患者诱导治疗后的一线巩固方案。
  • [1] Anderson KC. Progress and paradigms in multiple myeloma[J]. Clin Cancer Res, 2016, 22:5419-5427. doi:  10.1158/1078-0432.CCR-16-0625
    [2] McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma[J]. Lancet, 1983, 2:822-824. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=6137651
    [3] Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome[J]. N Engl J Med, 1996, 335:91-97. doi:  10.1056/NEJM199607113350204
    [4] Child JA, Morgan GJ, Davies FE, et al. Medical research council adult leukaemia working party. High-dose chemo-therapy with hematopoietic stem-cell rescue for multiple myeloma[J]. N Engl J Med, 2003, 348:1875-1883. doi:  10.1056/NEJMoa022340
    [5] Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation[J]. Blood, 2011, 118:529-534. http://europepmc.org/abstract/MED/21482708
    [6] Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2003, 349:2495-2502. doi:  10.1056/NEJMoa032290
    [7] Bladé J, Rosiñol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy:long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA[J]. Blood, 2005, 106:3755-3759. http://www.tandfonline.com/servlet/linkout?suffix=CIT0008&dbid=16&doi=10.1517%2F14656566.7.2.195&key=10.1182%2Fblood-2005-03-1301
    [8] Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma:a phase Ⅱ study by the Intergroupe Francophone du Myélome[J]. J Clin Oncol, 2014, 32:2712-2717. doi:  10.1200/JCO.2013.54.8164
    [9] Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma:a systematic review and meta-analysis of randomized controlled trials[J]. Biol Blood Marrow Transplan, 2007, 13:183-196. doi:  10.1016/j.bbmt.2006.09.010
    [10] Sonneveld P, Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma:a meta-analysis of phase Ⅲ randomized, controlled trials[J]. J Clin Oncol, 2013, 31:3279-3287. doi:  10.1200/JCO.2012.48.4626
    [11] Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma:results of the IFM 2005-01 phase Ⅲ trial[J]. J Clin Oncol, 2010, 28:4621-4629. doi:  10.1200/JCO.2009.27.9158
    [12] Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma:results of the randomized phase Ⅲ HOVON-65/GMMG-HD4 trial[J]. J Clin Oncol, 2012, 30:2946-2955. doi:  10.1200/JCO.2011.39.6820
    [13] Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma:a randomized phase 3 PETHEMA/GEM study[J]. Blood, 2012, 120:1589-1596. http://www.tandfonline.com/servlet/linkout?suffix=CIT0047&dbid=16&doi=10.1080%2F17474086.2018.1437345&key=10.1182%2Fblood-2012-02-408922
    [14] Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma:a randomised phase 3 study[J]. Lancet, 2010, 376:2075-2085. doi:  10.1016/S0140-6736(10)61424-9
    [15] Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma[J]. N Engl J Med, 2014, 371:895-905. doi:  10.1056/NEJMoa1402888
    [16] Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma[J]. Blood, 2010, 116:679-686. http://europepmc.org/articles/PMC3324254/
    [17] Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with transplantation for myeloma[J]. N Engl J Med, 2017, 376:1311-1320. doi:  10.1056/NEJMoa1611750
    [18] Attal M, Harousseau JL, Leyvraz S, et al. Maintenance the-rapy with thalidomide improves survival in patients with multiple myeloma[J]. Blood, 2006, 108:3289-3294. http://europepmc.org/abstract/MED/16873668
    [19] Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure[J]. J Clin Oncol, 2009, 27:1788-1793. doi:  10.1200/JCO.2008.18.8573
    [20] Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma[J]. N Engl J Med, 2006, 354:1021-1030. doi:  10.1056/NEJMoa053583
    [21] Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalido-mide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities[J]. Blood, 2008, 112:3115-3121. http://www.ncbi.nlm.nih.gov/pubmed/18492953
    [22] Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma[J]. Blood, 2010, 115:1113-1120. doi:  10.1182/blood-2009-05-222539
    [23] Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma:MRC Myeloma IX results and meta-analysis[J]. Blood, 2012, 119:7-15. doi:  10.1182/blood-2011-06-357038
    [24] Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2012, 366:1782-1791. doi:  10.1056/NEJMoa1114138
    [25] McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma[J]. N Engl J Med, 2012, 366:1770-1781. doi:  10.1056/NEJMoa1114083
    [26] Michaelis LC, Saad A, Zhong X, et al. Salvage second hematopoietic cell transplantation in myeloma[J]. Biol Blood Marrow Transplant, 2013, 19:760-766. doi:  10.1016/j.bbmt.2013.01.004
    [27] Kumar SK, Lacy MQ, Dispenzieri A, et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma[J]. Cancer, 2012, 118:1585-1592. doi:  10.1002/cncr.26422
  • 加载中
计量
  • 文章访问数:  165
  • HTML全文浏览量:  7
  • PDF下载量:  251
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-07-13
  • 刊出日期:  2018-05-30

目录

    /

    返回文章
    返回